Cancer genome and tumor microenvironment: Reciprocal crosstalk shapes lung cancer plasticity.
cancer biology
cancer genome
immunology
inflammation
lung cancer
tumor microenvironment
Journal
eLife
ISSN: 2050-084X
Titre abrégé: Elife
Pays: England
ID NLM: 101579614
Informations de publication
Date de publication:
08 09 2022
08 09 2022
Historique:
received:
05
05
2022
accepted:
12
08
2022
entrez:
8
9
2022
pubmed:
9
9
2022
medline:
14
9
2022
Statut:
epublish
Résumé
Lung cancer classification and treatment has been revolutionized by improving our understanding of driver mutations and the introduction of tumor microenvironment (TME)-associated immune checkpoint inhibitors. Despite the significant improvement of lung cancer patient survival in response to either oncogene-targeted therapy or anticancer immunotherapy, many patients show initial or acquired resistance to these new therapies. Recent advances in genome sequencing reveal that specific driver mutations favor the development of an immunosuppressive TME phenotype, which may result in unfavorable outcomes in lung cancer patients receiving immunotherapies. Clinical studies with follow-up after immunotherapy, assessing oncogenic driver mutations and the TME immune profile, not only reveal the underlying potential molecular mechanisms in the resistant lung cancer patients but also hold the key to better treatment choices and the future of personalized medicine. In this review, we discuss the crosstalk between cancer cell genomic features and the TME to reveal the impact of genetic alterations on the TME phenotype. We also provide insights into the regulatory role of cellular TME components in defining the genetic landscape of cancer cells during tumor development.
Identifiants
pubmed: 36074553
doi: 10.7554/eLife.79895
pii: 79895
pmc: PMC9457687
doi:
pii:
Substances chimiques
Immunologic Factors
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2022, Mansouri et al.
Déclaration de conflit d'intérêts
SM, DH, TS, MK, RS No competing interests declared
Références
Proc Natl Acad Sci U S A. 2016 Dec 27;113(52):E8433-E8442
pubmed: 27956623
Science. 1996 Feb 9;271(5250):810-2
pubmed: 8628998
Sci Rep. 2022 Jun 13;12(1):9753
pubmed: 35697720
Clin Cancer Res. 2017 Jun 15;23(12):3012-3024
pubmed: 28039262
Open Access Maced J Med Sci. 2019 Jul 20;7(14):2391-2398
pubmed: 31592285
J Exp Med. 2021 Jan 4;218(1):
pubmed: 33601414
Nature. 2009 Nov 5;462(7269):104-7
pubmed: 19847165
J Immunother Cancer. 2021 Nov;9(11):
pubmed: 34772757
J Biol Chem. 1997 Sep 26;272(39):24113-6
pubmed: 9305854
Science. 2011 Mar 25;331(6024):1565-70
pubmed: 21436444
Biomolecules. 2020 Feb 15;10(2):
pubmed: 32075247
Sci Adv. 2021 Jun 18;7(25):
pubmed: 34144984
Mol Cell Biol. 2008 Jul;28(13):4407-23
pubmed: 18443042
Oncogene. 2002 Jul 4;21(29):4490-7
pubmed: 12085227
J Leukoc Biol. 1994 Nov;56(5):559-64
pubmed: 7964163
N Engl J Med. 2014 Dec 4;371(23):2189-2199
pubmed: 25409260
Nature. 2007 Dec 6;450(7171):903-7
pubmed: 18026089
Cell. 2017 Nov 30;171(6):1259-1271.e11
pubmed: 29107330
Cancer Cell. 2004 Nov;6(5):447-58
pubmed: 15542429
EMBO Rep. 2021 Dec 6;22(12):e52509
pubmed: 34698427
Cancers (Basel). 2019 Aug 16;11(8):
pubmed: 31426445
Transl Lung Cancer Res. 2017 Apr;6(2):196-211
pubmed: 28529902
Nat Rev Genet. 2021 Oct;22(10):627-644
pubmed: 34145435
Nat Rev Drug Discov. 2009 Jun;8(6):480-99
pubmed: 19483709
Cancers (Basel). 2021 Oct 26;13(21):
pubmed: 34771516
Cancer Discov. 2018 Jul;8(7):822-835
pubmed: 29773717
Science. 2015 Apr 3;348(6230):124-8
pubmed: 25765070
Cell Rep. 2015 Feb 10;10(5):726-739
pubmed: 25660023
Nat Rev Cancer. 2006 Dec;6(12):924-35
pubmed: 17109012
Sci Signal. 2010 Jan 19;3(105):cm1
pubmed: 20086235
Cancer Res. 2020 Oct 1;80(19):4025-4036
pubmed: 32616502
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
Cell. 2017 Feb 9;168(4):613-628
pubmed: 28187284
Cell. 2017 Nov 30;171(6):1272-1283.e15
pubmed: 29107334
Cell Metab. 2017 Feb 7;25(2):482
pubmed: 28178570
Nucleic Acids Res. 2013 Jan 7;41(1):90-109
pubmed: 23087373
Cancer Cell. 2018 Apr 9;33(4):676-689.e3
pubmed: 29622463
Eur Respir Rev. 2020 Oct 1;29(157):
pubmed: 33004525
Cancer Res. 2016 Jun 1;76(11):3189-99
pubmed: 27197187
Nat Rev Immunol. 2005 Aug;5(8):641-54
pubmed: 16056256
Nat Rev Cancer. 2009 Apr;9(4):302-12
pubmed: 19308069
Nature. 2017 Jun 1;546(7656):168-172
pubmed: 28538732
Science. 2019 Sep 6;365(6457):
pubmed: 31488662
Cell. 2021 Feb 4;184(3):596-614.e14
pubmed: 33508232
Lancet Oncol. 2020 Oct;21(10):1353-1365
pubmed: 32919526
Proc Natl Acad Sci U S A. 2014 Apr 15;111(15):5664-9
pubmed: 24706787
Cancer Cell. 2013 Feb 11;23(2):143-58
pubmed: 23352126
J Immunol Res. 2018 Aug 8;2018:6984948
pubmed: 30159341
Nat Commun. 2020 Jul 30;11(1):3801
pubmed: 32732879
Immunol Rev. 2018 Jan;281(1):124-137
pubmed: 29247991
Nature. 2014 Jul 31;511(7511):543-50
pubmed: 25079552
Lung Cancer. 2020 Nov;149:41-45
pubmed: 32956987
J Clin Invest. 2021 Jan 4;131(1):
pubmed: 32931483
Nat Genet. 2019 Jan;51(1):19-25
pubmed: 30559489
Immunity. 2019 Apr 16;50(4):778-795
pubmed: 30995499
Nature. 1998 Apr 9;392(6676):565-8
pubmed: 9560152
Mol Cell Biol. 1999 May;19(5):3485-95
pubmed: 10207072
Crit Rev Oncol Hematol. 2021 Jul;163:103374
pubmed: 34087341
Nat Rev Clin Oncol. 2022 Apr;19(4):237-253
pubmed: 34997230
Nat Rev Cancer. 2019 Sep;19(9):495-509
pubmed: 31406302
Cell. 2017 Jan 12;168(1-2):37-57
pubmed: 28086098
Science. 2017 Jan 20;355(6322):
pubmed: 28104840
Int Immunopharmacol. 2009 Jul;9(7-8):900-9
pubmed: 19336265
CA Cancer J Clin. 2019 Jan;69(1):7-34
pubmed: 30620402
Clin Cancer Res. 2021 Sep 1;27(17):4685-4689
pubmed: 34083238
Curr Pharm Des. 2017;23(32):4893-4905
pubmed: 28606052
N Engl J Med. 2003 Feb 6;348(6):567-8
pubmed: 12571271
Cold Spring Harb Perspect Med. 2018 Sep 4;8(9):
pubmed: 29229670
Cell Stem Cell. 2015 Jan 8;16(1):11-2
pubmed: 25575078
Front Immunol. 2021 Jan 27;11:621931
pubmed: 33584721
Cancer Res. 2018 Jan 1;78(1):7-14
pubmed: 29263151
Front Immunol. 2013 Nov 20;4:391
pubmed: 24312098
Proc Natl Acad Sci U S A. 2004 Feb 24;101(8):2434-9
pubmed: 14983027
Annu Rev Cell Dev Biol. 2006;22:287-309
pubmed: 16824016
Cancer Res. 2020 Oct 15;80(20):4414-4425
pubmed: 32699134
Nat Rev Cancer. 2009 Apr;9(4):239-52
pubmed: 19279573
CA Cancer J Clin. 2021 Jan;71(1):7-33
pubmed: 33433946
Nat Med. 2018 May;24(5):541-550
pubmed: 29686425
Nat Rev Drug Discov. 2009 Jan;8(1):33-40
pubmed: 19116625
Cold Spring Harb Perspect Med. 2014 Jun 02;4(6):
pubmed: 24890832
Int J Cancer. 2019 Sep 1;145(5):1432-1444
pubmed: 30784054
Trends Cancer. 2020 Aug;6(8):677-687
pubmed: 32409139
Nat Rev Mol Cell Biol. 2009 Jul;10(7):478-87
pubmed: 19546858
Sci Adv. 2020 Jun 05;6(23):eaaz6105
pubmed: 32548260
Cell. 2019 Mar 7;176(6):1502-1515.e10
pubmed: 30799036
Cytokine. 2022 Feb;150:155773
pubmed: 34844039
J Thorac Oncol. 2010 Dec;5(12):1883-6
pubmed: 21102257
N Engl J Med. 2018 May 31;378(22):2093-2104
pubmed: 29658845
J Thorac Dis. 2018 Sep;10(Suppl 26):S3084-S3087
pubmed: 30370085
Expert Rev Clin Immunol. 2014 May;10(5):593-619
pubmed: 24678812
Nat Rev Cancer. 2004 Jun;4(6):437-47
pubmed: 15170446
Mol Cell Biol. 2005 Nov;25(22):10097-110
pubmed: 16260623
N Engl J Med. 2017 Sep 21;377(12):1119-1131
pubmed: 28845751
Cancer Discov. 2017 Jun;7(6):596-609
pubmed: 28336552
Br J Cancer. 2014 Aug 26;111(5):927-32
pubmed: 25058349
Hematol Oncol Clin North Am. 2017 Feb;31(1):13-29
pubmed: 27912828
Sci Rep. 2021 Sep 2;11(1):17606
pubmed: 34475499
Cancer Res. 2020 Dec 15;80(24):5597-5605
pubmed: 33023946
J Thorac Oncol. 2015 Jun;10(6):910-23
pubmed: 25658629
Immunity. 2016 Aug 16;45(2):389-401
pubmed: 27521269
J Thorac Oncol. 2020 Jan;15(1):138-143
pubmed: 31605792
Science. 1976 Oct 1;194(4260):23-8
pubmed: 959840
Lung Cancer. 2021 Apr;154:161-175
pubmed: 33690091
Front Pharmacol. 2019 Jun 14;10:673
pubmed: 31258479
Sci Rep. 2015 Oct 06;5:14756
pubmed: 26439902
Front Immunol. 2021 Dec 21;12:689076
pubmed: 34992591
Nat Rev Drug Discov. 2018 Aug;17(8):588-606
pubmed: 30026524
Ann Oncol. 2019 Jan 1;30(1):44-56
pubmed: 30395155
Cell. 2020 Oct 1;183(1):28-45
pubmed: 32976797
Nat Biotechnol. 2021 Jul;39(7):819-824
pubmed: 33846646
Semin Cancer Biol. 2006 Aug;16(4):253-64
pubmed: 16904903
Cold Spring Harb Perspect Med. 2018 May 1;8(5):
pubmed: 28710260
Nat Rev Drug Discov. 2012 Aug;11(8):633-52
pubmed: 22850787
Nature. 2015 Aug 6;524(7563):47-53
pubmed: 26168399
Cell Commun Signal. 2020 Apr 7;18(1):59
pubmed: 32264958
Immunol Rev. 2012 Mar;246(1):379-400
pubmed: 22435567
Nat Rev Immunol. 2018 May;18(5):309-324
pubmed: 29379212
J Clin Invest. 2020 Jul 1;130(7):3560-3575
pubmed: 32229721
EMBO Rep. 2020 Oct 5;21(10):e50635
pubmed: 32964587
Proc Natl Acad Sci U S A. 2019 Jan 22;116(4):1361-1369
pubmed: 30545915
Oncotarget. 2017 Jul 25;8(30):50209-50220
pubmed: 28430586
Cancer Discov. 2015 Aug;5(8):860-77
pubmed: 26069186
Signal Transduct Target Ther. 2021 Nov 15;6(1):386
pubmed: 34776511
Oncoimmunology. 2017 Jul 26;6(11):e1356145
pubmed: 29147605
Nat Rev Cancer. 2021 Aug;21(8):481-499
pubmed: 34083781
Cell. 2000 Jan 7;100(1):57-70
pubmed: 10647931
J Cell Sci. 2020 Mar 6;133(5):
pubmed: 32144194
J Biomed Sci. 2017 Apr 4;24(1):26
pubmed: 28376884
Nature. 2013 Aug 22;500(7463):415-21
pubmed: 23945592
Nat Commun. 2019 Apr 29;10(1):1930
pubmed: 31036827
Cell Death Differ. 2019 Jan;26(2):199-212
pubmed: 30538286
Elife. 2019 Jun 24;8:
pubmed: 31232687
Cold Spring Harb Perspect Biol. 2009 Oct;1(4):a000034
pubmed: 20066092
Semin Immunol. 2013 Dec 15;25(6):430-8
pubmed: 24183701
Oncotarget. 2017 Jul 18;8(29):48436-48452
pubmed: 28467800
Cancer Discov. 2021 Feb;11(2):282-292
pubmed: 33127846
N Engl J Med. 2020 Oct 29;383(18):1711-1723
pubmed: 32955177
Nat Rev Cancer. 2019 Feb;19(2):110-117
pubmed: 30470829
Nature. 2021 Jul;595(7868):578-584
pubmed: 34135508
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Proc Natl Acad Sci U S A. 2017 Mar 14;114(11):2934-2939
pubmed: 28246332
Cancer Res. 2006 Apr 15;66(8):4198-207
pubmed: 16618742
Nat Immunol. 2005 May;6(5):439-45
pubmed: 15843800
Sci Rep. 2021 Jul 29;11(1):15455
pubmed: 34326381
N Engl J Med. 2017 Jun 22;376(25):2415-2426
pubmed: 28636851
Int J Mol Sci. 2020 Dec 17;21(24):
pubmed: 33348923
Trends Cancer. 2020 Jul;6(7):605-618
pubmed: 32610070
Mol Syst Biol. 2019 Jun 19;15(6):e8746
pubmed: 31217225
Science. 1968 Dec 13;162(3859):1243-8
pubmed: 5699198
Cancer Discov. 2013 Dec;3(12):1355-63
pubmed: 24078774
Mod Pathol. 2012 Jan;25 Suppl 1:S18-30
pubmed: 22214967
Lancet. 2017 Oct 21;390(10105):1833-1842
pubmed: 28855077
J Proteome Res. 2021 Jan 1;20(1):751-762
pubmed: 33253581
Cancer Treat Rev. 2017 Nov;60:24-31
pubmed: 28866366
Cancer Immunol Immunother. 2022 Feb;71(2):251-265
pubmed: 34125345
Sci Rep. 2019 Jul 17;9(1):10353
pubmed: 31316109
J Immunol. 2011 Mar 15;186(6):3462-71
pubmed: 21300825
J Thorac Oncol. 2015 Sep;10(9):1243-1260
pubmed: 26291008
Cell. 2017 Nov 30;171(6):1301-1315.e14
pubmed: 29195074
Clin Med (Lond). 2018 Apr 1;18(Suppl 2):s41-s46
pubmed: 29700092
Nat Med. 1997 Feb;3(2):177-82
pubmed: 9018236
Nature. 2016 Nov 17;539(7629):390-395
pubmed: 27799657
EMBO Mol Med. 2019 Nov 7;11(11):e10427
pubmed: 31566909
Nature. 2012 Jan 18;481(7381):306-13
pubmed: 22258609
Int J Cancer. 2016 Jun 1;138(11):2549-61
pubmed: 26537995
Mol Cancer Res. 2014 Jan;12(1):3-13
pubmed: 24442106
Cancer Cell. 2021 Aug 9;39(8):1023-1027
pubmed: 33989512